Catherine Chirouze

Catherine Chirouze

Auto-generated profile, based on publicly available information

Catherine Chirouze

Maladies Infectieuses et Tropicales-Centre Hospitalier Universitaire, Besançon F-25030, France; UMR-CNRS 6249 Chrono-Environnement, Université Bourgogne Franche-Comté, F-25000 Besançon, France

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2020 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
BMBasile Mouhat
Basile Mouhat
MBMatthieu Besutti
Matthieu Besutti
KBKevin Bouiller
Kevin Bouiller
FGFranck Grillet
Franck Grillet
CMCharles Monnin
Charles Monnin
NMNicolas Meneveau
Nicolas Meneveau
Background: Coronavirus disease 2019 (COVID-19) may predispose to venous thromboembolism. We determined factors independently associated with computed tomography pulmonary angiography (CTPA)-confirmed pulmonary embolism (PE) in hospitalised severe COVID-19 patients.Methods: Among all (n=349) patients hospitalised for COVID-19 in a university hospital in a French region with a high rate of COVID-19, we analysed patients who underwent CTPA for clinical signs of severe disease (oxygen saturation measured by pulse oximetry ≤93% or breathing rate ≥30 breaths·min−1) or rapid clinical worsening. Multivariable analysis was performed using Firth penalised maximum likelihood estimates.Results: 162 (46.4%) patients underwent CTPA (mean±sdage 65.6±13.0 years; 67.3% male (95% CI 59.5–75.5%). PE was diagnosed in 44 (27.2%) patients. Most PEs were segmental and the rate of PE-related right ventricular dysfunction was 15.9%. By multivariable analysis, the only two significant predictors of CTPA-confirmed PE were D-dimer level and the lack of any anticoagulant therapy (OR 4.0 (95% CI 2.4–6.7) per additional quartile and OR 4.5 (95% CI 1.1–7.4), respectively). Receiver operating characteristic curve analysis identified a D-dimer cut-off value of 2590 ng·mL−1to best predict occurrence of PE (area under the curve 0.88, p2590 ng·mL−1was associated with a 17-fold increase in the adjusted risk of PE.Conclusion: Elevated D-dimers (>2590 ng·mL−1) and absence of anticoagulant therapy predict PE in hospitalised COVID-19 patients with clinical signs of severity. These data strengthen the evidence base in favour of systematic anticoagulation, and suggest wider use of D-dimer guided CTPA to screen for PE in acutely ill hospitalised patients with COVID-19.

31 May 2022 in Journal of Infection
Verified
Journal Article
Closed access
SSSarah Soueges
Sarah Soueges
KBKevin Bouiller
Kevin Bouiller
EBElisabeth Botelho-Nevers
Elisabeth Botelho-Nevers
AGAmandine Gagneux-Brunon
Amandine Gagneux-Brunon
CCCatherine Chirouze
Catherine Chirouze
FAFlorence Ader
Florence Ader

1 July 2020 in Hellenic Journal of Cardiology
Verified
Journal Article
Open access
Giuseppe GattiGiuseppe Gatti
Giuseppe Gatti
SCSidney Chocron
Sidney Chocron
JOJean-François Obadia
Jean-François Obadia
XDXavier Duval
Xavier Duval
BIBernard Iung
Bernard Iung
APAndrea Perrotti
Andrea Perrotti
The accuracy of surgical scores in predicting in-hospital mortality for nonsurgically treated patients with infective endocarditis (IE) has not yet been explored. Patients with definite IE who did not undergo valve surgery were selected from the database of seven French administrative areas (Association pour l'Étude et la Prévention de l'Endocardite Infectieuse [AEPEI] Registry, 2008). The patients were scored using (a) six systems specifically devised to predict in-hospital mortality after surgery for IE, (b) three commonly used risk scores for heart surgery, and (c) a risk score for predicting six-month mortality in IE after either surgery or medical therapy. Calibration (Hosmer-Lemeshow test) and discriminatory power (receiver operating characteristic [ROC] analysis) were assessed for each score. Areas under ROC curves were compared one-to-one (Hanley-McNeil method). A total of 192 patients (mean age, 65.2±15.2 years) were considered for analysis. There were 38 (19.8%) in-hospital deaths. Age >70 years (p=0.001), Staphylococcus aureus as causal agent (p=0.05), and severe sepsis (p=0.027) were independent predictors of in-hospital mortality. Despite many differences in the number and type of variables, all but two of the investigated scores showed good calibration (p>0.66). However, discriminatory power was satisfactory (area under ROC curve >0.70) only for three of the scores specific for IE and two of the scores used to predict mortality after cardiac surgery. Among the 10 surgical scores evaluated in this study, five could be adopted to predict in-hospital mortality even for IE patients receiving medical treatment only.

26 January 2021 in Current HIV Research
Verified
Journal Article
Closed access
PDF file
JLJennifer Lagoutte-Renosi
Jennifer Lagoutte-Renosi
MFMylène Flammang
Mylène Flammang
CCCatherine Chirouze
Catherine Chirouze
GBGeneviève Beck-Wirth
Geneviève Beck-Wirth
FBFabienne Bozon
Fabienne Bozon
PMPatrice Muret
Patrice Muret
Background: Tenofovir disoproxil fumarate is a prodrug of tenofovir diphosphate that exposes patients to renal toxicity over the long term. Tenofovir alafenamide, a new prodrug, now makes it possible to reduce toxicity, but at the cost of an alteration in lipid profile. There is currently no recommendation for follow-up of lipid profile when switching from tenofovir disoproxil fumarate to tenofovir alafenamide. Objective: Our study aimed to evaluate the effects on renal function and lipid profile of a switch from tenofovir disoproxil fumarate to tenofovir alafenamide, and the consequences for patient management. Methods: Demographic, clinical and biological data was recorded from a retrospective clinical cohort study in real-life, including patients who switched from tenofovir disoproxil fumarate to tenofovir alafenamide. A descriptive analysis of the study population, with a comparison of biological parameters using the paired Student t test for paired data was performed. Results: From January 2016 to January 2019, a total of 103 patients were included. There was no significant difference in renal function before vs after the switch in therapy (p=0.29 for creatinine, p=0.30 for phosphoremia). We observed a change in lipid profile, with a significant increase in total cholesterol (p=0.0006), HDL cholesterol (p=0.0055) and triglycerides (p=0.0242). Four patients received lipid-lowering therapy after switching. Conclusion: In patients who switch from tenofovir disoproxil fumarate to tenofovir alafenamide, lipid profile is altered, and may require initiation of lipid-lowering therapy. It seems necessary to monitor lipid parameters after this switch, despite the absence of an official recommendation.

1 June 2019 in Medecine Et Maladies Infectieuses
Verified
Journal Article
Closed access
PLP. Lalloz
P. Lalloz
KBKevin Bouiller
Kevin Bouiller
CCC. Chirouze
C. Chirouze
VGVincent Gendrin
Vincent Gendrin
APAnais Potron
Anais Potron
TKTimothée KLOPFENSTEIN
Timothée KLOPFENSTEIN

1 June 2016 in Medecine Et Maladies Infectieuses
Verified
Journal Article
Closed access
FBF. Bozon
F. Bozon
MPM. Parolini
M. Parolini
LGL. De Gentile
L. De Gentile
JFJ. Faucher
J. Faucher
CCC. Chirouze
C. Chirouze